Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

This commentary provides the authors' perspective on the article Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, which has recently been published in The Lancet Oncology.